Reported 27 days ago
AbbVie raised its 2024 profit forecast after strong sales of its immunology drugs Skyrizi and Rinvoq, which helped the company surpass Wall Street's third-quarter earnings expectations. This improvement is particularly notable as sales of its former flagship drug, Humira, continue to decline, primarily due to competition from cheaper biosimilars. AbbVie anticipates its adjusted profit will reach between $10.90 and $10.94 per share, up from previous estimates.
Source: YAHOO